Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2019-11-15

FDA Approved: TRESIBA — Supplemental Application (Novo Nordisk)

View source ↗

Summary

FDA approved a supplemental application for Tresiba (insulin degludec) filed by Novo Nordisk.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tresiba (insulin degludec)

Snippet

SUPPL AP for TRESIBA (INSULIN DEGLUDEC)